MPL signalling boosts HSPC subsets but does not alter infection parameters.

<p>C57BL/6 mice -/ + <i>S. mansoni</i> were treated with human TPO 3x per week at week 8 and 9 post-infection with (A) blood platelets and (B) liver CD41 + platelet-leukocyte aggregrates (PLA) determined at wk10. (C) Platelet MPV in mice treated with romiplostim as Fig. 6A. (D) Rep...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Joanna H. Greenman (22693783) (author)
مؤلفون آخرون:	Shinjini Chakraborty (22693786) (author), Lucie Moss (9765678) (author), Paul C. Armstrong (22693789) (author), Paul M. Kaye (7255013) (author), Ian S. Hitchcock (9384203) (author), James P. Hewitson (12791480) (author)
منشور في:	2025
الموضوعات:	Biochemistry Medicine Microbiology Immunology Cancer Science Policy Hematology Infectious Diseases Environmental Sciences not elsewhere classified Biological Sciences not elsewhere classified phenotypic analysis shows myeloid cell activation included elevated expression impacted host survival immune cell function distinct activation phenotype bone marrow megakaryocytes activation marker relmα dampen macrophage activation alter macrophage phenotype induced parasite death reduced platelet output whether platelets control relatively well understood infection also reduced div >< p reduced platelet levels associated liver macrophages macrophage responses parasite eggs lower levels liver macrophages platelet uptake vivo </ vitro </ systemic tpo studies indicated specific manner pharmacological treatment mouse model modulating classical mediated depletion leukocyte aggregates less clear key modulators fully reversed either promote deficient mice data indicate
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

MPL signalling boosts HSPC subsets but does not alter infection parameters.

مواد مشابهة